Atlas market file · Equity · United States
Bio-Rad Laboratories, Inc.BIO-B
- Last close
- 337.00
- Change
- +0.00%
- 96-bar range
- 244.54 – 337.00
- As of
- 6 Aug 2026
Bio-Rad Laboratories, Inc. is a laboratory analytical instruments issuer listed as BIO-B on NYSE. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
BIO-B
Equity · evidence first
Static Daily profile candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Source rail: Yahoo Finance chart API (BIO-B). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for BIO-B. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
BIO-B public profile
Laboratory analytical instruments issuer. Bio-Rad Laboratories, Inc. is connected to current market context, cited company sources and its retained research file.
Bio-Rad Laboratories, Inc. trades as BIO-B on NYSE. Bio-Rad Laboratories, Inc. (BIO-B) has a latest verified close of 337.00, unchanged, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files BIO-B under USA Stocks for browsing.
What changed for Bio-Rad Laboratories, Inc. today
Bio-Rad Laboratories (BIO-B) reported a staggering $527.1 million net loss in Q1 2026 despite generating $592.1 million in revenue, raising eyebrows across the life sciences sector. The company, which provides specialized tools for biological research and clinical diagnostics, saw sales decline 4.2% on a currency-neutral basis, with both its Life Science (39% of revenue) and Clinical Diagnostics (61%) segments lag. Inventory levels also surged by $29.9 million, hinting at either aggressive stockpiling or a bet on future demand that the market hasn’t yet validated.
Geographically, Bio-Rad remains heavily exposed to the Americas (46% of revenue), followed by EMEA (35%) and APAC (19%). The company’s gross margin edged up 1.1%, but this was overshadowed by a 180-basis-point improvement in operating margin-a statistical silver lining in an otherwise stormy quarter. Notably, insider transactions in May 2026 saw executives selling shares, while the board approved a new incentive plan in April, sparking questions about alignment between leadership and shareholders.
Regulatory risks loom large: the company warned that reduced reimbursements for clinical lab services under laws like the Affordable Care Act could further pressure margins. With $507.2 million in cash and $1.06 billion in short-term investments, liquidity isn’t an immediate concern, but the persistent cash burn ($22 million used in operations vs. $108 million generated) demands closer scrutiny. Investors will watch whether Bio-Rad can stabilize its top line or if the inventory buildup turns into a fire sale.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
Open an Atlas research path on BIO-B
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep BIO-B research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
BIO-B FAQ
What is Bio-Rad Laboratories, Inc. (BIO-B)?Bio-Rad Laboratories, Inc. (BIO-B) has a latest verified close of 337.00, unchanged, dated 6 Aug 2026. Use this page to check the price chart, company context,...
Bio-Rad Laboratories, Inc. (BIO-B) has a latest verified close of 337.00, unchanged, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for BIO-B?Bio-Rad Laboratories, Inc. (BIO-B) has a latest verified close of 337.00, unchanged, dated 6 Aug 2026. It brings the latest available chart, company context, cited...
Bio-Rad Laboratories, Inc. (BIO-B) has a latest verified close of 337.00, unchanged, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files BIO-B under USA Stocks for browsing.
How often is the BIO-B page updated?The BIO-B public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The BIO-B public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for BIO-B?The BIO-B file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NYSE:BIO-B. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The BIO-B file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NYSE:BIO-B. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on BIO-B?Yes. The workstation can open BIO-B, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open BIO-B, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this BIO-B page investment advice?No. The BIO-B page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The BIO-B page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →